Carfilzomib is a novel proteasome inhibitor utilized in the battle against cancer. This drug works by hindering the activity of the proteasome, a cellular complex responsible for the breakdown of proteins. By restricting this process, carfilzomib leads the accumulation of damaged or abnormal proteins, ultimately causing cell death. Carfilzomib has

Tepotinib, also known as {MSC2156119|the experimental compound|this agent), represents a promising breakthrough in the targeting of NSCLC, particularly in individuals harboring MET exon 14 skipping. This targeted tyrosine kinase blocker|TKI shows substantial activity against cancer spread in laboratory assessments and first human research. Its mech

Matrine is a naturally occurring alkaloid primarily found from the roots of the *Sophora* genus, specifically *Sophora flavescens*. Numerous studies have analyzed its therapeutic properties, revealing a range of remarkable benefits. Matrine has demonstrated immunomodulatory effects, making it appealing as a potential therapy for various conditions.